Alleviation of diabetic nephropathy by zinc oxide nanoparticles in streptozotocin-induced type 1 diabetes in rats.
Alomari, G
Al-Trad, B
Hamdan, S
Aljabali, AAA
Al Zoubi, MS
Al-Batanyeh, K
Qar, J
Eaton, GJ
Alkaraki, AK
Alshaer, W
Haifawi, S
Jemon, K
Chellappan, DK
Dua, K
Tambuwala, MM
- Publisher:
- Institution of Engineering and Technology (IET)
- Publication Type:
- Journal Article
- Citation:
- IET nanobiotechnology, 2021, 15, (5), pp. 473-483
- Issue Date:
- 2021-07
Open Access
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is open access.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Alomari, G | |
dc.contributor.author | Al-Trad, B | |
dc.contributor.author | Hamdan, S | |
dc.contributor.author | Aljabali, AAA | |
dc.contributor.author | Al Zoubi, MS | |
dc.contributor.author | Al-Batanyeh, K | |
dc.contributor.author | Qar, J | |
dc.contributor.author | Eaton, GJ | |
dc.contributor.author | Alkaraki, AK | |
dc.contributor.author | Alshaer, W | |
dc.contributor.author | Haifawi, S | |
dc.contributor.author | Jemon, K | |
dc.contributor.author | Chellappan, DK | |
dc.contributor.author |
Dua, K |
|
dc.contributor.author | Tambuwala, MM | |
dc.date.accessioned | 2021-12-28T00:39:40Z | |
dc.date.available | 2020-11-06 | |
dc.date.available | 2021-12-28T00:39:40Z | |
dc.date.issued | 2021-07 | |
dc.identifier.citation | IET nanobiotechnology, 2021, 15, (5), pp. 473-483 | |
dc.identifier.issn | 1751-8741 | |
dc.identifier.issn | 1751-875X | |
dc.identifier.uri | http://hdl.handle.net/10453/152541 | |
dc.description.abstract | This study examines the effect of nanoparticles with zinc oxides (ZnONPs) on diabetic nephropathy, which is the primary cause of mortality for diabetic patients with end-stage renal disease. Diabetes in adult male rats was induced via intraperitoneal injection of streptozotocin. ZnONPs were intraperitoneally administered to diabetic rats daily for 7 weeks. Diabetes was associated with increases in blood glucose level, 24-h urinary albumin excretion rate, glomerular basement membrane thickness, renal oxidative stress markers, and renal mRNA or protein expression of transforming growth factor-β1, fibronectin, collagen-IV, tumour necrosis factor-α and vascular endothelial growth factor-A. Moreover, the expression of nephrin and podocin, and the mRNA expression of matrix metalloproteinase-9 were decreased in the diabetic group. These changes were not detected in the control group and were significantly prevented by ZnONP treatment. These results provide evidence that ZnONPs ameliorate the renal damage induced in a diabetic rat model of nephropathy through improving renal functionality; inhibiting renal fibrosis, oxidative stress, inflammation and abnormal angiogenesis; and delaying the development of podocyte injury. The present findings may help design the clinical application of ZnONPs for protection against the development of diabetic nephropathy. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.publisher | Institution of Engineering and Technology (IET) | |
dc.relation.ispartof | IET nanobiotechnology | |
dc.relation.isbasedon | 10.1049/nbt2.12026 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | 0906 Electrical and Electronic Engineering, 1003 Industrial Biotechnology | |
dc.subject.classification | Nanoscience & Nanotechnology | |
dc.subject.mesh | Kidney | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Rats | |
dc.subject.mesh | Diabetic Nephropathies | |
dc.subject.mesh | Diabetes Mellitus, Experimental | |
dc.subject.mesh | Diabetes Mellitus, Type 1 | |
dc.subject.mesh | Zinc Oxide | |
dc.subject.mesh | Streptozocin | |
dc.subject.mesh | Vascular Endothelial Growth Factor A | |
dc.subject.mesh | Male | |
dc.subject.mesh | Nanoparticles | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Diabetes Mellitus, Experimental | |
dc.subject.mesh | Diabetes Mellitus, Type 1 | |
dc.subject.mesh | Diabetic Nephropathies | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Kidney | |
dc.subject.mesh | Male | |
dc.subject.mesh | Nanoparticles | |
dc.subject.mesh | Rats | |
dc.subject.mesh | Streptozocin | |
dc.subject.mesh | Vascular Endothelial Growth Factor A | |
dc.subject.mesh | Zinc Oxide | |
dc.title | Alleviation of diabetic nephropathy by zinc oxide nanoparticles in streptozotocin-induced type 1 diabetes in rats. | |
dc.type | Journal Article | |
utslib.citation.volume | 15 | |
utslib.location.activity | United States | |
utslib.for | 0906 Electrical and Electronic Engineering | |
utslib.for | 1003 Industrial Biotechnology | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health/Graduate School of Health | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy | |
utslib.copyright.status | open_access | * |
dc.date.updated | 2021-12-28T00:39:38Z | |
pubs.issue | 5 | |
pubs.publication-status | Published | |
pubs.volume | 15 | |
utslib.citation.issue | 5 |
Abstract:
This study examines the effect of nanoparticles with zinc oxides (ZnONPs) on diabetic nephropathy, which is the primary cause of mortality for diabetic patients with end-stage renal disease. Diabetes in adult male rats was induced via intraperitoneal injection of streptozotocin. ZnONPs were intraperitoneally administered to diabetic rats daily for 7 weeks. Diabetes was associated with increases in blood glucose level, 24-h urinary albumin excretion rate, glomerular basement membrane thickness, renal oxidative stress markers, and renal mRNA or protein expression of transforming growth factor-β1, fibronectin, collagen-IV, tumour necrosis factor-α and vascular endothelial growth factor-A. Moreover, the expression of nephrin and podocin, and the mRNA expression of matrix metalloproteinase-9 were decreased in the diabetic group. These changes were not detected in the control group and were significantly prevented by ZnONP treatment. These results provide evidence that ZnONPs ameliorate the renal damage induced in a diabetic rat model of nephropathy through improving renal functionality; inhibiting renal fibrosis, oxidative stress, inflammation and abnormal angiogenesis; and delaying the development of podocyte injury. The present findings may help design the clinical application of ZnONPs for protection against the development of diabetic nephropathy.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph